Vertex Pharmaceuticals - Vertex Pharmaceuticals 在2023财年实现了强劲的收入增长，新的管道机会预示着未来的增长[3] - Vertex Pharmaceuticals 以其创新的囊性纤维化疗法而闻名，最近的批准项目包括与 CRISPR Therapeutics 合作的 Exa-Cel 和 VX-548，这些项目有望为公司的收入流提供多样化[4] - 预计 VX-548 和 Vanzacaftor Triple for CF 的 FDA 申请将是 2024 财年的两大增长催化剂，市场低估了 VX-548 的收入潜力，这可能为公司增加数十亿美元的市值[5]

BENGALURU, India--(BUSINESS WIRE)--UiPath (NYSE: PATH), a leading enterprise automation software company, today announced at the UiPath DevCon 2024 event a host of new features in its platform designed to enable developers to build, test, and accelerate implementation of automations. UiPath DevCon gathers hundreds of AI and automation developers, architects, engineers, testers, and product managers for a deep dive into innovation and collaboration possibilities for automation creators within the UiPath B ...

In the latest trading session, UiPath (PATH) closed at $25.67, marking a -1.31% move from the previous day. This change lagged the S&P 500's 0.58% gain on the day. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 0.3%.Shares of the enterprise automation software developer witnessed a gain of 20.31% over the previous month, beating the performance of the Business Services sector with its gain of 7.73% and the S&P 500's gain of 4.61%.Market participants will be closely following the ...

Deloitte与UiPath战略联盟 - Deloitte与UiPath宣布进一步扩大战略联盟，推出Deloitte的Smart Finance for Growth Companies，为成长型公司财务团队提供定制化的托管服务[1] - 该服务允许公司快速建立或扩展他们的自动化计划，并利用智能自动化的力量提升他们的能力和生产力[1] - 由UiPath提供支持的Deloitte的这一服务将帮助成长型公司在财务功能内快速利用AI驱动自动化，然后在整个业务中扩展效果[5] 智能自动化计划 - Deloitte的智能自动化计划可以帮助成长型公司实现现代化流程，提供更多有用的决策信息，解放人力，提高效率[4] - UiPath的AI驱动自动化软件可以自动提取结构化和非结构化文档中的数据，消除耗时且容易出错的手动处理，同时还可以应用于财务流程如供应商管理、发票处理和现金应用[4] - Deloitte的自动化计划可以帮助成长型公司解锁这些好处，即使缺乏人力或经验，也可以建立和运行智能自动化计划[4]

UiPath财务表现 - UiPath当前财年的共识盈利预期为$0.47，同比增长+235.7%[6] - 下一个财年的共识盈利预期为$0.49，同比增长+5.8%[7] - UiPath上一季度营收为$325.92百万美元，同比增长+24.1%[11] UiPath股票评级 - UiPath的Zacks Rank评级为3（持有），基于盈利预期修订等因素[8] UiPath盈利预期 - 分析师对UiPath当前季度每股收益预期为$0.15，与去年同期持平[5] - UiPath在过去四个季度中均超过共识每股收益预期[13] UiPath价值评级 - UiPath的Zacks Value Style Score为D，表明其相对同行公司交易溢价[17]

UiPath公司财报公布 - UiPath公司将于2024年1月31日结束的第四季度和全年财务报告于2024年3月13日周三市场收盘后公布[1] - UiPath将在2024年3月13日举行财报电话会议，讨论公司财务状况[2] UiPath公司简介 - UiPath是一家领先的企业自动化软件公司，致力于提升知识工作水平，通过AI驱动的业务自动化平台为组织提供全面的自动化解决方案，帮助组织在不断变化的时代中生存和繁荣[3]

UiPath (PATH) shares ended the last trading session 8.2% higher at $26.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.9% gain over the past four weeks.The price appreciation seems to be driven by investor’s positive expectation from the company’s performance going further post its collaboration with Deloitte to accelerate business transformation. The alliance expansion with Deloitte empowers UiPath with mark ...

Key PointsUiPath is the leading provider of artificial intelligence (AI) powered software bots for robotic process automation (RPA) and business process automation (BPA) solutions.UiPath has integrated and infused AI into its tools, driving annual net-dollar retention rates to 121% and ARR growing at 24% YoY.UiPath is generating net losses and has a 7.4% short interest.5 stocks we like better than UiPathUiPath Inc. NYSE: PATH is the world’s largest provider of end-to-end robotic process automation (RPA) and ...

UiPath (PATH) closed at $23.48 in the latest trading session, marking a +1.43% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.82%. Elsewhere, the Dow gained 0.41%, while the tech-heavy Nasdaq added 0.95%.The enterprise automation software developer's shares have seen an increase of 2.8% over the last month, not keeping up with the Business Services sector's gain of 6.18% and the S&P 500's gain of 5.59%.The upcoming earnings release of UiPath will be of great interest to investors. ...

股价表现 - UiPath (PATH) 最近的股价为 $23.11，较前一天收盘价上涨了 +0.57% [1] - UiPath 的股价在过去一个月中上涨了 1.82%，表现优于商业服务行业的增长率 0.44% 和标普500指数的增长率 1.58% [2] 财务表现 - UiPath 预计每股收益为 $0.08，同比下降了 46.67%，预计季度营收为 $383.32 百万美元，同比增长了 24.23% [3] 市场关注 - 分析师和投资者将密切关注 UiPath 的业绩披露，以及近期对 UiPath 的分析师预期调整 [4]